Sold as Eraxis. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Anidulafungin (sold as Eraxis), first approved Feb 17, 2006, with 1 new use approved and 0 published complete response letters.
| Eraxis | Part D | $354K | -27% | 108 |
| Eraxis | Part B | $4K | -38% | 0 |
| Echinocandin Added to Standard Treatment for Severe Pneumocystis PneumoniaPneumocystis Jirovecii Pneumonia · McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 | Not yet recruiting | Oct 28, 2026 |
| A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated CandidemiaCandidemia · Augusta University | — | Not yet recruiting | Apr 3, 2025 |
| Feb 17, 2006 | EraxisNDA 21632 · New molecular entity | Vicuron Holdings | 15 | Marketed |
| Feb 17, 2006 | EraxisNDA 21948 · TYPE 6 | Pfizer | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer